Tags » William Ackman

Teva in talks to buy Allergan's generic drug business

Teva Pharmaceutical Industries Ltd is in advanced talks to buy Allergan Plc’s generic drug business following a thus far unsuccessful effort to acquire peer Mylan NV, according to a person familiar with the matter. 359 more words


Another activist investor takes on Macy's this time

Starboard Value Investors garnered a lot of PR recently, with its micro-critical look at the operations of Darden Restaurants before taking over the chain. Now its sights are set on Macy’s, in hopes to “unlock the asset value” of Macy’s real estate. 151 more words

Dick Seesel

Lessons from a New Self-Earner: Learning about Investing

I love the internet, regardless about how much I complain about YouTube trolls and the constant influx of baby pictures on my Facebook stream. I love it because I can learn almost anything with the internet. 515 more words

Andre C Griffiths

[Reuters] In Herbalife’s nutrition clubs, Ackman’s attacks fail to resonate

This article first appeared at Reuters.com.

By Jeffrey Dastin and Daina Beth Solomon

(Reuters) – New York hedge fund manager William Ackman says Herbalife is a pyramid scheme that exploits the poor.  1,175 more words


Bill Ackman just acknowledged the one thing most people already knew about his Herbalife event

It’s a rare admission for a cocksure hedge fund boss. But that’s what we just heard from Bill Ackman, who acknowledged during an interview with Bloomberg… 254 more words

Epic Fail: Investors Balk at Ackman's Efforts to Destroy Herbalife

By Mathew Turner at the Inquisitr 07/23/2014




In a momentous flop and significantly overblown introduction to what was supposed to be the death blow to Herbalife, William Ackman (a.k.a Herbalife’s self proclaimed arch enemy), failed to deliver on what he described as the most important presentation of his career. 35 more words


Allergan’s CEO ready to make deals to fend off Valeant offer

Allergan CEO David Pyott is ready to strike some deals in a bid to fend off a $53 billion hostile offer from Valeant Pharmaceuticals and activist investor William Ackman. 216 more words